STOCK TITAN

PDS Biotechnology proposes 1-for-10–1-for-35 reverse split

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
PRE 14A

Rhea-AI Filing Summary

PDS Biotechnology Corporation (PDSB) is seeking approval for a 1-for-10 to 1-for-35 reverse stock split through a charter amendment. If stockholders approve, the Board would decide whether to implement it, select the ratio, and could act on or before December 31, 2027; approval does not require the Board to proceed.

PDSB had not regained compliance with Nasdaq’s $1.00 minimum bid-price requirement, which requires the closing bid price to be at least $1.00 for 10 consecutive business days. The stock closed at $0.8073 on November 19, 2026, and the initial 180-calendar-day compliance period ends January 26, 2027. If compliance is not regained, PDSB may be eligible for an additional 180-day period subject to conditions, or Nasdaq may commence delisting proceedings. The company says a reverse split may not sustain a higher share price or ensure continued listing. 114,856,548 common shares were outstanding as of November 20, 2026.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • None.

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Nasdaq’s $1.00 minimum-bid-price deficiency remains unresolved: PDSB’s stock closed at $0.8073 on November 19, 2026, and the initial compliance period ends January 26, 2027. Failure to regain compliance could lead to delisting proceedings.

Filing Explained

If implemented, the split would preserve holders’ percentage ownership except for fractional-share cash-outs, but leave 300 million authorized shares while expanding unissued, unreserved shares from 123,047,504 to 282,304,753–294,944,217. Later issuance could dilute holders, though no specific issuance plans are disclosed.

Proposed reverse split ratio 1-for-10 to 1-for-35 Stockholder approval would authorize the Board to select a ratio within the range.
Closing stock price $0.8073 per share November 19, 2026; Nasdaq Capital Market.
Minimum bid price $1.00 per share Nasdaq continued-listing requirement.
Initial compliance period deadline January 26, 2027 End of the initial 180-calendar-day period to regain compliance.
Common shares outstanding 114,856,548 shares As of November 20, 2026.
Authorized common shares 300,000,000 shares The proposal would leave the authorized amount unchanged.
minimum bid price requirement regulatory
"below the minimum bid price requirement for continued listing"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
authorized but unissued shares financial
"increase the number of authorized but unissued shares"
Authorized but unissued shares are the number of shares a company is legally allowed to create but has not yet issued to investors, employees, or other parties. They matter to investors because issuing those reserved shares in the future can dilute existing ownership, raise cash, or be used for employee pay and acquisitions—like having empty slots a company can fill later, which changes voting power and per-share value.
broker non-votes regulatory
"Broker non-votes occur when a beneficial owner"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
fractional shares financial
"No fractional shares of Common Stock will be issued"
Fractional shares are portions of a whole share of a stock or fund, allowing investors to own less than one full unit. They make it possible to invest a specific dollar amount rather than buy whole shares, like buying a slice of a pizza instead of the entire pie. For investors this lowers the cost barrier, helps with diversification, and lets you reinvest dividends or purchase expensive stocks in small, precise amounts.
recapitalization financial
"intended to be treated as a “recapitalization”"
Recapitalization is a deliberate change to a company's mix of debt and equity—how much it borrows versus how much is funded by shareholders—accomplished by issuing or repaying debt, buying back shares, or issuing new shares. It matters to investors because it alters the company's risk profile, potential returns and cash flow stability: increasing debt can amplify returns but raises the chance of financial stress, while adding equity can dilute ownership but lower default risk—like swapping between a mortgage and savings to reshape household finances.
backup withholding financial
"subject to information reporting and backup withholding"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What reverse stock split ratio is PDSB asking stockholders to approve?

PDSB is asking stockholders to approve a reverse split ratio from 1-for-10 to 1-for-35. If approved, the Board may select any whole-number ratio within that range and may implement the split on or before December 31, 2027, or decide not to proceed.

Why is PDSB proposing a reverse stock split?

PDSB says the proposal is intended to address Nasdaq’s $1.00 minimum bid-price requirement. Nasdaq notified the company that its bid price had closed below $1.00 for 30 consecutive business days. PDSB had not regained compliance, which requires a closing bid price of at least $1.00 for 10 consecutive business days.

Would PDSB’s reverse split reduce its authorized common shares?

No. The proposal would leave 300 million authorized common shares unchanged. If implemented, reducing outstanding shares without reducing the authorized amount would increase authorized but unissued shares. PDSB says it has no specific plans, arrangements, agreements, or understandings to issue those additional shares.

How would PDSB handle fractional shares in a reverse split?

Stockholders otherwise entitled to fractional shares would receive cash in lieu of the fractional share. The payment would equal the fraction multiplied by the common stock’s closing price on the trading day immediately before the effective time, without interest or deduction.

How many votes are needed to approve PDSB’s reverse split proposal?

Approval requires the affirmative vote of a majority of votes cast. Abstentions and broker non-votes are not considered votes cast and have no effect on the outcome.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

TABLE OF CONTENTS

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.  )
Filed by the Registrant ☒
Filed by a Party other than the Registrant  ☐
Check the appropriate box:
☒
Preliminary Proxy Statement
 ☐
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 ☐
Definitive Proxy Statement
 ☐
Definitive Additional Materials
 ☐
Soliciting Material under §240.14a-12
 
PDS BIOTECHNOLOGY CORPORATION
(Name of Registrant as Specified In Its Charter)
 
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
 
Payment of Filing Fee (Check the appropriate box):
☒
No fee required.
 ☐
Fee paid previously with preliminary materials.
 ☐
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

TABLE OF CONTENTS

PRELIMINARY PROXY STATEMENT DATED NOVEMBER 20, 2026 — SUBJECT TO COMPLETION
PDS Biotechnology Corporation
303A College Road East, Princeton, NJ 08540
 
NOTICE OF SPECIAL MEETING OF STOCKHOLDERS
 
To Be Held on December [ ], 2026
Dear Stockholder:
You are cordially invited to attend the Special Meeting of Stockholders (the “Special Meeting”) of PDS Biotechnology Corporation, a Delaware corporation (the “Company”, “PDS”, or “PDS Biotech”). The Special Meeting will be held on December [ ], 2026, at 8 a.m. Eastern Time. The Special Meeting will be held virtually via live webcast. Stockholders will be able to attend the Special Meeting and submit questions and vote their shares during the Special Meeting by visiting www.virtualshareholdermeeting.com/PDSB2026SM and entering your 16-digit control number included on the proxy card or voting instruction form that you receive. The Special Meeting will be held for the following purposes:
1.
To approve an amendment to our Eighth Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect, in the sole discretion of the Board of Directors of the Company (the “Board”) at any time on or before December 31, 2027, a reverse stock split of the Company’s common stock, par value $0.00033 per share (the “Common Stock”), at a ratio to be determined by the Board within a range of 1-for-10 to 1-for-35 (or any whole number in between), without reducing the authorized number of shares of the Common Stock, and without further approval or authorization of our stockholders (the “Reverse Stock Split Proposal”); and
2.
To consider and vote upon an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Stock Split Proposal (the “Adjournment Proposal”).
These items of business are more fully described in the proxy statement accompanying this notice. The record date for the Special Meeting is November 20, 2026 (the “Record Date”). Only stockholders of record at the close of business on that date may vote at the Special Meeting or any adjournment thereof.
This Notice of Special Meeting and Proxy Statement, together with a proxy card or voting instruction form, are first being mailed to stockholders on or about November [ ], 2026. Whether or not you expect to attend the meeting, please vote over the telephone or on the internet, as instructed in these materials, or by returning your signed proxy card in the envelope provided as promptly as possible in order to ensure your representation at the meeting. Voting instructions are on your proxy card or voting instruction form and are included in the accompanying proxy statement. Even if you have voted by proxy, you may still vote online if you attend the meeting via the internet.
Important Notice Regarding the Availability of Proxy Materials for the Special Meeting of Stockholders to Be
Held on December [ ], 2026.
 
The Proxy Statement is available at www.proxyvote.com
 
 
 
 
By Order of the Board of Directors
 
 
 
 
 
 
 
 
 
 
 
Chief Executive Officer
 
 
 
 
 
 
 

TABLE OF CONTENTS

TABLE OF CONTENTS
 
 
 
 
 
 
 
Page
About the Special Meeting
 
 
1
Proposal No. 1 — Reverse Stock Split Proposal
 
 
7
Proposal No. 2 — Adjournment Proposal
 
 
16
Security Ownership of Certain Beneficial Owners and Management
 
 
17
Householding of Proxy Materials
 
 
18
Where You Can Find Additional Information
 
 
19
Other Matters
 
 
20
Appendix A - Certificate of Amendment to the Eighth Amended and Restated Certificate of Incorporation
 
 
A-1
 
 
 
 
i

TABLE OF CONTENTS

PDS Biotechnology Corporation
303A College Road East
Princeton, NJ 08540
 
PROXY STATEMENT
FOR THE SPECIAL MEETING OF STOCKHOLDERS
 
To be Held on December [ ], 2026
ABOUT THE SPECIAL MEETING
QUESTIONS AND ANSWERS ABOUT PROCEDURAL MATTERS
Why am I receiving these proxy materials?
We are making these proxy materials available to you on or about November [_], 2026, because our board of directors (our “Board”) is soliciting your proxy to vote at the Special Meeting of Stockholders (the “Special Meeting”) of PDS Biotechnology Corporation, a Delaware corporation (the “Company,” “PDS,” “PDS Biotech,” “we,” “us” and “our”), and at any postponements, adjournments or continuations thereof, for the purpose of considering and acting upon the matters set forth herein. This proxy statement (this “Proxy Statement”) and the enclosed form of proxy are being furnished in connection with that solicitation. This Proxy Statement includes information that we are required to provide to you by the Securities and Exchange Commission (the “SEC”), and that is designed to assist you in voting your shares. The Special Meeting will be held virtually on December [_], 2026, at 8 a.m. Eastern Time via live webcast.
How will the proxy materials be delivered?
We are mailing a full set of our proxy materials, including this Proxy Statement and a proxy card or voting instruction form, to our stockholders. You may also access the proxy materials on the internet at www.proxyvote.com.
If you would like to reduce the environmental impact and the costs incurred by us in printing and distributing proxy materials, you may elect to receive all future proxy materials electronically via email or the internet. To sign up for electronic delivery, please follow the instructions provided with your proxy materials and on your proxy card or voting instruction form.
What is included in the proxy materials?
The proxy materials include:
•
This Proxy Statement for the Special Meeting;
•
The proxy card or a voting instruction form for the Special Meeting.
How do I attend the Special Meeting?
The Special Meeting will be held on December [ ], 2026, at 8 a.m. Eastern Time via a virtual stockholder meeting through which you can listen to the meeting, submit questions and vote online. The Special Meeting can be accessed by visiting www.virtualshareholdermeeting.com/PDSB2026SM and entering your 16-digit control number which is included on the proxy card or voting instruction form that will be mailed to you. The virtual meeting platform is fully supported across browsers and devices running the most updated version of applicable software and plugins. Participants should ensure that they have a strong internet connection wherever they intend to participate in the meeting.
We recommend that you log in a few minutes before the Special Meeting on December [ ], 2026, to ensure you are logged in when the meeting starts. Online check-in will begin at 7:55 a.m. Eastern Time.
Can I ask questions at the Special Meeting?
Stockholders participating in the virtual meeting may submit questions or comments during the meeting.
If you would like to submit a question, you may do so by joining the virtual Special Meeting at www.virtualshareholdermeeting.com/PDSB2026SM and typing your question in the box in the Special Meeting portal.
1

TABLE OF CONTENTS

To help ensure that we have a productive and efficient meeting, and in fairness to all stockholders in attendance, you will also find posted our rules of conduct for the Special Meeting when you log in prior to its start. In accordance with the rules of conduct, we ask that you limit your remarks to one brief question or comment that is relevant to the Special Meeting or our business and remarks that are respectful of your fellow stockholders and meeting participants. Questions may be grouped by topic by our management with a representative question read aloud and answered. In addition, questions may be ruled as out of order if they are, among other things, irrelevant to our business, related to pending or threatened litigation, disorderly, repetitious of statements already made, or in furtherance of the speaker’s own personal, political or business interests. Questions will be addressed in the Q&A portion of the Special Meeting, as time permits.
What if I need technical assistance accessing or participating in the virtual Special Meeting?
If you encounter any difficulties accessing the virtual Special Meeting during the check-in or meeting time, please call the technical support number that will be posted on the virtual meeting login page. Technical support will be available starting at 7:55 a.m. Eastern Time on December [ ], 2026.
Who can vote at the Special Meeting?
Only stockholders of record at the close of business on November 20, 2026 (the “Record Date”) will be entitled to vote at the Special Meeting. On the Record Date, there were 114,856,548 shares of the Company’s common stock, par value $0.00033 per share (the “Common Stock”), outstanding and entitled to vote.
Stockholder of Record: Shares Registered in Your Name
If on the Record Date your shares were registered directly in your name with our transfer agent, Computershare Trust Company, N.A., then you are a stockholder of record. As a stockholder of record, you may vote at the Special Meeting or vote by proxy. Whether or not you plan to attend the Special Meeting, we urge you to vote your shares by proxy in advance of the Special Meeting through the internet, by telephone, or by completing and returning a printed proxy card to ensure your vote is counted.
Beneficial Owner: Shares Registered in the Name of a Broker, Bank or Other Agent
If on the Record Date your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in “street name” and the proxy materials, together with a voting instruction form, are being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Special Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend the Special Meeting. If your voting instruction form indicates that you may vote your shares through the www.proxyvote.com website, then you may access, participate in, and vote at the Special Meeting with the 16-digit control number indicated on that voting instruction form. Otherwise, you should contact your broker or other agent (preferably at least five days before the Special Meeting) and obtain a “legal proxy” in order to log into the Special Meeting as a stockholder and be able to vote at the meeting.
What am I voting on?
There are two matters scheduled for a vote:
Proposal 1:
To approve an amendment to the Company’s Eighth Amended and Restated Certificate of Incorporation, as amended (the “Charter”), to effect, in the sole discretion of the Board at any time on or before December 31, 2027, a reverse stock split of the Common Stock, at a ratio to be determined by the Board within a range of 1-for-10 to 1-for-35 (or any whole number in between), without reducing the authorized number of shares of the Common Stock, and without further approval or authorization of our stockholders (the “Reverse Stock Split Proposal”); and
Proposal 2:
To approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Stock Split Proposal (the “Adjournment Proposal”).
Why is the Company seeking approval for the Reverse Stock Split Proposal?
On July 30, 2026, we received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Common Stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
2

TABLE OF CONTENTS

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided an initial period of 180 calendar days, or until January 26, 2027, to regain compliance with the minimum bid price requirement. If we do not regain compliance within this initial 180 calendar day period, we may be eligible for an additional 180 calendar day compliance period, subject to satisfaction of certain conditions, or Nasdaq may commence delisting proceedings.
As of the date hereof, we have not regained compliance with the minimum bid price requirement since the closing bid price of the Common Stock has not been at least $1.00 per share for a minimum of ten consecutive business days. To cure the deficiency, we may conduct the reverse stock split of the Common Stock for which we are seeking stockholder approval in this Proxy Statement. On November 19, 2026, the closing price of our Common Stock as reported on the Nasdaq Capital Market was $0.8073 per share.
Our Board has approved the reverse stock split as a potential means of increasing the share price of the Common Stock and may choose to implement it if other options are unavailable, undesirable, or insufficient. Our Board believes that maintaining our listing on the Nasdaq Capital Market provides a broader market for the Common Stock and facilitates the use of the Common Stock in financing and other transactions. We expect the reverse stock split, if effected, to facilitate the continuation of such listing. We cannot assure you, however, that the reverse stock split, if effected, will result in an increase in the per share price of the Common Stock, or if it does, how long the increase would be sustained, if at all, or whether the increase will be proportional to the reverse stock split ratio.
If our stockholders approve the Reverse Stock Split Proposal, our Board in its sole discretion will determine whether to effect the reverse stock split. Our Board reserves the right to elect not to effect a reverse stock split, including any or all reverse stock split ratios within the proposed range, if it determines, in its sole discretion, that implementing a reverse stock split is not in the best interest of the Company and its stockholders. For more information, see “Proposal No. 1 — Reverse Stock Split Proposal” contained elsewhere in this Proxy Statement.
What if another matter is properly brought before the Special Meeting?
The Board knows of no other matters that will be presented for consideration at the Special Meeting. If any other matters are properly brought before the Special Meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment.
How do I vote?
Whether you hold shares directly as the stockholder of record or indirectly as the beneficial owner of shares held for you by a broker or other nominee (i.e., in “street name”), you may direct your vote without attending the Special Meeting. You may vote by granting a proxy or, for shares you hold in street name, by submitting voting instructions to your broker or nominee. In most instances, you will be able to do this by internet, telephone or by mail. Please refer to the summary instructions below and those included on your proxy card or, for shares you hold in street name, the voting instruction form provided by your broker or nominee.
Stockholder of Record: Shares Registered in Your Name
If you are a stockholder of record, you may vote at the Special Meeting, vote by proxy over the telephone, vote by proxy through the internet, or vote by proxy using a proxy card that you may request or has been mailed to you. Whether or not you plan to attend the Special Meeting, we urge you to vote by proxy to ensure your vote is counted.
•
Via Webcast: You may attend the Special Meeting via the internet and vote during the Special Meeting. The Special Meeting can be accessed by visiting www.virtualshareholdermeeting.com/PDSB2026SM and entering your 16-digit control number which is included on your proxy card. Please have your proxy card in hand when you access the website and then follow the instructions.
•
By Mail: You may vote by proxy by filling out the proxy card you received and returning it promptly in the envelope provided. If you return your signed proxy card to us before the Special Meeting, we will vote your shares as you direct.
•
By Telephone: To vote over the telephone, dial toll-free (800) 690-6903 using a touch-tone phone and follow the recorded instructions. Have your 16-digit control number available when you call. You will be asked to provide the company number and control number from your proxy card. Your telephone vote must be received by 11:59 p.m., Eastern Time on December [ ], 2026 to be counted.
3

TABLE OF CONTENTS

•
Via the Internet: To vote through the internet before the Special Meeting, go to www.proxyvote.com and follow the on-screen instructions. Please have your 16-digit control number found on your proxy card or voting instruction form in hand when you access the website and then follow the instructions. Your internet vote must be received by 11:59 p.m., Eastern Time on December [ ], 2026 to be counted.
Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Agent
If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received the proxy materials and a voting instruction form from that organization rather than from us. Simply follow the instructions on the voting instruction form to ensure that your vote is counted. Alternatively, you may vote by telephone or on the internet as instructed by your broker or bank. To vote online at the Special Meeting, please follow the instructions at www.virtualshareholdermeeting.com/PDSB2026SM. You will need the 16-digit control number, which is included on the voting instruction form that will be mailed to you. Whether or not you plan to attend the Special Meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the Special Meeting and vote online even if you have already voted by proxy.
Internet proxy voting is provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.
How many votes do I have?
On each matter to be voted upon, you have one vote for each share of Common Stock you owned as of the Record Date.
What happens if I do not vote?
Stockholder of Record: Shares Registered in Your Name
If you are a stockholder of record and do not vote by completing your proxy card, by telephone, through the Internet or at the Special Meeting, your shares will not be voted.
Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Agent
See “What are broker non-votes?” below.
What if I return a proxy card or otherwise vote but do not make specific choices?
If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted,
•
“For” the Reverse Stock Split Proposal; and
•
“For” the Adjournment Proposal.
If any other matter is properly presented at the Special Meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.
Who is paying for this proxy solicitation?
We will pay for the entire cost of soliciting proxies as well as hosting the virtual-only Special Meeting. In addition to these proxy materials, our directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the reasonable cost of forwarding proxy materials to beneficial owners. In addition, we have engaged Morrow Sodali to assist in the solicitation of proxies and provide related advice and information support, for a fee that is not expected to exceed $12,000 in total.
What does it mean if I receive more than one set of proxy materials?
If you receive more than one set of proxy materials, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on each proxy card or voting instruction form you receive to ensure that all of your shares are voted.
4

TABLE OF CONTENTS

Can I change my vote after submitting my proxy?
Yes. You can revoke your proxy at any time before the final vote at the Special Meeting.
Stockholder of Record: Shares Registered in Your Name
If you are the record holder of your shares, you may revoke your proxy in any one of the following ways:
•
You may submit another properly completed proxy card with a later date.
•
You may grant a subsequent proxy by telephone or through the internet.
•
You may send a timely written notice that you are revoking your proxy to our Secretary at PDS Biotechnology Corporation at 303A College Road East, Princeton, NJ 08540.
•
You may attend the Special Meeting via the internet and vote online at the meeting. Simply attending the Special Meeting will not, by itself, revoke your proxy.
Your most current proxy card or telephone or internet proxy is the one that is counted.
Beneficial Owner: Shares Registered in the Name of Broker, Bank or Other Agent
If your shares are held by your broker, bank or other agent as a nominee, you should follow the instructions provided by your broker, bank or other agent.
How are votes counted?
Before the Special Meeting, our Board will appoint one or more inspectors of election for the meeting. The inspector(s) will determine the number of shares represented at the meeting, the existence of a quorum and the validity and effect of proxies. The inspector(s) will also receive, count, and tabulate ballots and votes and determine the results of the voting on each matter that comes before the Special Meeting.
What are “broker non-votes?”
Broker non-votes occur when a beneficial owner of shares held in street name does not give instructions to the broker, bank or other agent that holds the shares as to how to vote on matters deemed “non-routine.” Each of the Reverse Stock Split Proposal and the Adjournment Proposal is considered a “routine” matter under applicable stock exchange rules. Accordingly, in the absence of timely directions from you, your broker will have discretion to vote your shares on each of the proposals. We do not expect any broker non-votes with respect to these proposals. Broker non-votes, if any, will be counted for purposes of calculating whether a quorum is present at the Special Meeting but will not be counted for purposes of determining the number of votes present and entitled to vote or votes cast.
How many votes are needed to approve each proposal?
•
Proposal No. 1 – The approval of the Reverse Stock Split Proposal requires the affirmative vote of a majority of the votes cast on this proposal at the Special Meeting, in accordance with Section 242(d)(2) of the General Corporation Law of the State of Delaware (the “DGCL”). Stockholder abstentions are not considered votes cast and thus will have no effect on the outcome of this proposal. Because this proposal is considered a “routine” matter, brokers will have discretionary authority to vote on this proposal and broker non-votes are not expected.
•
Proposal No. 2 – The approval of the Adjournment Proposal requires the affirmative vote of the majority of the shares of our Common Stock present in person or by remote communication, if applicable, or represented by proxy at the Special Meeting and entitled to vote thereon. Stockholder abstentions are considered shares present and entitled to vote on this proposal, and thus, will have the same effect as a vote “Against” this proposal. Broker non-votes will have no effect on the outcome of this proposal.
What is the quorum requirement?
A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of the outstanding shares entitled to vote are present at the Special Meeting or represented by proxy. Virtual attendance at the Special Meeting constitutes presence in person for purposes of a quorum at the Special Meeting.
5

TABLE OF CONTENTS

Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote at the Special Meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, either the chairman of the Special Meeting or the holders of a majority of shares present at the Special Meeting or represented by proxy may adjourn the Special Meeting to another date.
How can I find out the results of the voting at the Special Meeting?
Preliminary voting results will be announced at the Special Meeting. In addition, final voting results will be published in a current report on Form 8-K that we expect to file within four business days after the Special Meeting. If final voting results are not available to us in time to file a Form 8-K within four business days after the Special Meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to us, file an additional Form 8-K to publish the final results.
Who can help answer your questions?
If you have questions about the Special Meeting or would like additional copies of this Proxy Statement, you should contact Spencer Brown at PDS Biotechnology Corporation, 303A College Road East, Princeton, NJ 08540, or by phone at (800) 208-3343.
6

TABLE OF CONTENTS

PROPOSAL 1
 
REVERSE STOCK SPLIT PROPOSAL
Background
The Board has approved and recommended the Reverse Stock Split Proposal to approve an amendment to the Charter that would effect a reverse stock split of all of our Common Stock at a ratio to be determined by the Board within a range of 1-for-10 to 1-for-35 (or any whole number in between), to be effected in the sole discretion of the Board at any time on or before December 31, 2027, without reducing the authorized number of shares of the Common Stock, and without further approval or authorization of our stockholders (the “Reverse Stock Split”). The Reverse Stock Split Proposal provides that the Board will have sole discretion to elect, at any time on or before December 31, 2027, as it determines to be in our best interest, whether or not to effect the Reverse Stock Split, and, if so, the number of shares of Common Stock, between and including 1-for-10 and 1-for-35, which will be combined into one share of Common Stock. The Board believes that the availability of alternative reverse stock split ratios will provide it with the flexibility to implement the Reverse Stock Split in a manner designed to maximize the anticipated benefits for us and our stockholders.
If the Board determines that effecting the Reverse Stock Split is in our best interest, the Reverse Stock Split will become effective upon the filing of an amendment to the Charter with the Secretary of State of the State of Delaware (the “Delaware Secretary of State”). The amendment filed thereby will set forth the number of shares to be combined into one share of Common Stock within the limits set forth in this proposal. Except for adjustments that may result from the treatment of fractional shares as described below, each stockholder will hold the same percentage of our outstanding Common Stock immediately following the Reverse Stock Split as such stockholder holds immediately prior to the Reverse Stock Split.
If the Board elects to effect the Reverse Stock Split, following stockholder approval, for a Reverse Stock Split in the range of 1-for-10 to 1-for-35, the number of issued and outstanding shares of Common Stock would be reduced in accordance with a reverse stock split ratio selected by the Board from among those set forth in this proposal. Except for adjustments that may result from the treatment of fractional shares as described below, each stockholder will hold the same percentage of outstanding Common Stock immediately following the Reverse Stock Split as such stockholder held immediately prior to the Reverse Stock Split. The par value of the Common Stock would remain unchanged at $0.00033 per share. The Reverse Stock Split would not change the number of authorized shares of Common Stock. There are currently no specific plans, arrangements, agreements or understandings for the issuance of the additional authorized but unissued and unreserved shares of Common Stock that would be created by the Reverse Stock Split.
The text of the proposed amendment to the Charter to effect the Reverse Stock Split is included as Appendix A to this Proxy Statement. However, such text is subject to amendment to include such changes as may be required by the office of the Delaware Secretary of State or as the Board deems necessary and advisable to effect the Reverse Stock Split. If the Reverse Stock Split Proposal is approved by our stockholders, we will have the authority to file one amendment with the Secretary of State of the State of Delaware, which will become effective upon its filing or the effective time set forth in the amendment. The Board has determined that the amendment is advisable and in the best interests of the Company and its stockholders and has submitted the amendment for consideration by our stockholders at the Special Meeting.
Reasons for the Reverse Stock Split
Although the proposed Reverse Stock Split will not have the effect of increasing the Company’s equity market capitalization, we believe that implementing the Reverse Stock Split could provide benefits to the Company and our existing stockholders in a number of ways, including:
1.
Maintain our listing on the Nasdaq Capital Market. Our Common Stock is traded on the Nasdaq Capital Market. On July 30, 2026, we received a notice from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for the Common Stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided an initial period of 180 calendar days, or until January 26, 2027, to regain compliance with the minimum bid price requirement.
As of the date hereof, we have not regained compliance with the minimum bid price requirement since the closing bid price of the Common Stock has not been at least $1.00 per share for a minimum of ten consecutive
7

TABLE OF CONTENTS

business days. To cure the deficiency, we may conduct the Reverse Stock Split for which we are seeking stockholder approval in this Proxy Statement. On November 19, 2026, the closing price of the Common Stock as reported on the Nasdaq Capital Market was $0.8073 per share.
Our Board has approved the Reverse Stock Split as a potential means of increasing the share price of the Common Stock and may choose to implement it if other options are unavailable, undesirable, or insufficient. Our Board believes that maintaining our listing on the Nasdaq Capital Market provides a broader market for the Common Stock and facilitates the use of the Common Stock in financing and other transactions. We expect the Reverse Stock Split, if effected, to facilitate the continuation of such listing. We cannot assure you, however, that the Reverse Stock Split, if effected, will result in an increase in the per share price of the Common Stock, or if it does, how long the increase would be sustained, if at all, or whether the increase will be proportional to the reverse stock split ratio.
If our stockholders approve the Reverse Stock Split Proposal, our Board in its sole discretion will determine whether to effect the Reverse Stock Split. Our Board reserves the right to elect not to effect a reverse stock split, including any or all reverse stock split ratios within the proposed range, if it determines, in its sole discretion, that implementing a reverse stock split is not in the best interest of the Company and its stockholders.
If our stockholders do not approve the Reverse Stock Split Proposal, the Company may be delisted from Nasdaq due to our failure to maintain a minimum bid price for the Common Stock of $1.00 per share as required by Nasdaq. Reducing the number of our issued and outstanding shares of Common Stock should, absent other factors, increase the per share market price of the Common Stock, although we cannot provide any assurance that, following the Reverse Stock Split, our minimum bid price would remain over the minimum bid price requirement of Nasdaq.
Stockholders should also be aware that, under Nasdaq Listing Rule 5810(c)(3)(A)(iv), if the Company effects a reverse stock split and the Common Stock subsequently fails to meet the minimum bid price requirement within one year following such reverse stock split, the Company will not be eligible for any compliance period and Nasdaq will issue a delisting determination. In addition, if the Company has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, the Company will not be eligible for a compliance period. Nasdaq rules also provide that a reverse stock split that causes the Company to fall below another continued listing requirement, such as the minimum number of publicly held shares or round-lot holders, will not be considered to cure the bid price deficiency. The Board intends to take these limitations into account in selecting the final ratio.
The Board has considered the potential harm to the Company and its stockholders should Nasdaq delist the Common Stock from the Nasdaq Capital Market. Delisting could adversely affect the liquidity of the Common Stock because alternatives, such as the OTCQB or the Pink Market maintained by OTC Markets Group Inc., are generally considered to be less liquid and less efficient markets. An investor likely would find it less convenient to sell, or to obtain accurate quotations in seeking to buy, the Common Stock on an over-the-counter market. Many investors likely would not buy or sell the Common Stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, the Common Stock would be subject to SEC rules as a “penny stock,” which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in the Common Stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. For these reasons and others, delisting would adversely affect the liquidity, trading volume and price of the Common Stock, causing the value of an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations, including our ability to attract and retain qualified employees and to raise capital. The Board believes that the Reverse Stock Split is a potentially effective means for us to maintain compliance with the rules of Nasdaq and to avoid, or at least mitigate, the likely adverse consequences of the Common Stock being delisted from Nasdaq by producing the immediate effect of increasing the bid price of the Common Stock.
8

TABLE OF CONTENTS

2.
Stock Price Volatility. We understand that a higher stock price may increase the acceptability of the Common Stock to investors who may not find shares of Common Stock attractive at the current market price due to the trading volatility often associated with stocks below certain prices.
3.
Transaction Costs. Investors also may be dissuaded from purchasing stocks below certain prices because the brokerage commissions, as a percentage of the total transaction value, tend to be higher for such low-priced stocks.
4.
Stock Price Requirements. We understand that many brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers or by restricting or limiting the ability to purchase such stocks on margin.
Board Discretion to Implement or Abandon Reverse Stock Split
If the Reverse Stock Split is approved by the Company’s stockholders at the Special Meeting, the actual Reverse Stock Split will be effected, if at all, only upon a subsequent determination by the Board that the Reverse Stock Split is, at such time, in the best interests of the Company and its stockholders. Such determination will be based upon many factors, which are described in the following section. Notwithstanding approval of the Reverse Stock Split by the stockholders, the Board may, in its sole discretion (without further action by our stockholders), abandon the proposed amendment and determine, prior to the effectiveness of any filing with the Delaware Secretary of State, not to effect the Reverse Stock Split, as permitted under Section 242(c) of the DGCL. By voting in favor of the Reverse Stock Split, you are also expressly authorizing the Board to determine not to proceed with, and to abandon, the Reverse Stock Split if it should so decide. If the Board decides not to implement any of the Reverse Stock Split on or before December 31, 2027, further stockholder approval would be required prior to implementing any reverse stock split.
Criteria to be Used for Decision to Effect a Reverse Stock Split
If the stockholders approve the Reverse Stock Split, the Board will be authorized to proceed with the Reverse Stock Split in its sole discretion. In determining whether to proceed with the Reverse Stock Split, the Board expects to consider a number of factors, including market conditions, existing and expected trading prices of the Common Stock, our actual and projected financial performance, the Nasdaq Capital Market listing requirements, our additional funding requirements, overall trends in the stock market, business developments, and the amount of our authorized but unissued Common Stock. The Board does not intend for this transaction to be the first step in a series of plans or proposals of a “going private” transaction within the meaning of Rule 13e-3 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
The Board believes that stockholder approval of a range of potential reverse stock split ratios is in the best interests of our Company and stockholders because it is not possible to predict market conditions at the time the Reverse Stock Split would be implemented. We believe that a range of reverse stock split ratios provides us with the most flexibility to achieve the desired results of the Reverse Stock Split. The reverse stock split ratio to be selected by our Board will be no less than 1-for-10 and not more than 1-for-35.
Determination of the Reverse Stock Split Ratio
The selection of the specific reverse stock split ratio will be based on several factors, including, among other things:
•
our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market;
•
the per share price of the Common Stock immediately prior to the Reverse Stock Split;
•
the expected stability of the per share price of the Common Stock following the Reverse Stock Split;
•
the likelihood that the Reverse Stock Split will result in increased marketability and liquidity of the Common Stock;
•
the anticipated impact of the Reverse Stock Split on our ability to raise additional financing;
•
which split ratio would result in the greatest overall reduction in our administrative costs;
•
general economic conditions in our industry; and
•
our market capitalization before and after the Reverse Stock Split.
9

TABLE OF CONTENTS

We believe that granting our Board the authority to set the ratio for the Reverse Stock Split is essential because it allows us to take these factors into consideration and to react to changing market conditions. If the Board chooses to implement the Reverse Stock Split, we will make a public announcement regarding the determination of the reverse stock split ratio.
Principal Effects of the Reverse Stock Split
Effects on Issued and Outstanding Shares. If the Reverse Stock Split is effected, it will reduce the total number of issued and outstanding shares of the Common Stock, including any shares held by the Company as treasury shares, by a reverse stock split ratio of 1-for-10 to 1-for-35. Accordingly, each of our stockholders will own fewer shares of the Common Stock as a result of the Reverse Stock Split. However, the Reverse Stock Split will affect all stockholders uniformly and will not affect any stockholder’s percentage ownership interest in the Company, except to the extent that the Reverse Stock Split would result in an adjustment to a stockholder’s ownership of the Common Stock due to the treatment of fractional shares in the Reverse Stock Split. Therefore, voting rights and other rights and preferences of the holders of the Common Stock will not be affected by the Reverse Stock Split (other than as a result of the treatment of fractional shares). The Common Stock issued pursuant to the Reverse Stock Split will remain fully paid and nonassessable, and the par value per share of the Common Stock will remain $0.00033. The Reverse Stock Split will not constitute a “going private” transaction subject to Rule 13e-3 under the Exchange Act.
As of the Record Date, approximately 114,856,548 shares of the Common Stock were outstanding. No shares of preferred stock are currently outstanding. For purposes of illustration, if the Reverse Stock Split is effected at a ratio of 1-for-10, the number of issued and outstanding shares of the Common Stock after the Reverse Stock Split would be approximately 11,485,654 shares (other than as a result of the treatment of fractional shares), and if the Reverse Stock Split is effected at a ratio of 1-for-35, the number of issued and outstanding shares of the Common Stock after the Reverse Stock Split would be approximately 3,281,615 shares (other than as a result of the treatment of fractional shares).
Effects on Outstanding Equity Awards and Plans. If the Reverse Stock Split is effected, the terms of equity awards granted under our Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan, as amended, the 2018 Stock Incentive Plan, and the 2019 Inducement Plan, as amended (collectively, the “Equity Plans”), including the price per share covered by each outstanding award and the number of shares covered by each outstanding award, will be proportionally adjusted to maintain their economic value, subject to adjustments for any fractional shares as described herein. In addition, the total number of shares of the Common Stock that may be the subject of future grants under the Equity Plans, as well as any plan limits on the size of such grants, will be adjusted and proportionately decreased as a result of the Reverse Stock Split.
Effects on Section 409A Compliance. The adjustment of stock options and other equity awards in connection with the Reverse Stock Split is intended to be effected in a manner that complies with the requirements of Section 409A of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) and Section 424 of the Code and the Treasury Regulations thereunder. The Company does not intend for the Reverse Stock Split to result in the grant of a new stock right or a modification of an existing stock right within the meaning of Treasury Regulations Section 1.409A-1(b)(5)(v).
Effects on Voting Rights. Proportionate voting rights and other rights of the holders of the Common Stock would not be affected by the Reverse Stock Split (other than as a result of the treatment of fractional shares). For example, a holder of 1% of the voting power of the outstanding Common Stock immediately prior to the effective time of the Reverse Stock Split (the “Effective Time”) would continue to hold 1% of the voting power of the outstanding Common Stock after the Reverse Stock Split (other than as a result of the treatment of fractional shares).
Effects on Authorized Share Capital. The total number of shares of capital stock that we are authorized to issue will not be affected by the Reverse Stock Split and will remain at 300,000,000 shares of Common Stock, par value $0.00033 per share, and 5,000,000 shares of preferred stock, par value $0.00033 per share.
Effects on the Number of Shares of Common Stock Available for Future Issuance. By reducing the number of shares outstanding without reducing the number of shares of available but unissued Common Stock, the Reverse Stock Split will increase the number of authorized but unissued shares. The Board believes the increase is appropriate for use to fund the future operations of the Company. Although the Company does not have any pending acquisitions for which shares are expected to be used, the Company may also use authorized shares in connection with the financing of future acquisitions.
10

TABLE OF CONTENTS

Although the Reverse Stock Split would not have any dilutive effect on our stockholders, the Reverse Stock Split without a reduction in the number of shares authorized for issuance would reduce the proportion of shares owned by our stockholders relative to the number of shares authorized for issuance, giving the Board an effective increase in the authorized shares available for issuance, in its discretion. The Board from time to time may deem it to be in the best interests of the Company to enter into transactions and other ventures that may include the issuance of shares of the Common Stock. If the Board authorizes the issuance of additional shares subsequent to the Reverse Stock Split, the dilution to the ownership interest of our existing stockholders may be greater than would occur had the Reverse Stock Split not been effected.
Treatment of Fractional Shares in the Reverse Stock Split
No fractional shares of Common Stock will be issued as a result of the Reverse Stock Split. Instead, any stockholder who would otherwise be entitled to receive a fractional share of Common Stock as a result of the Reverse Stock Split will receive a cash payment in lieu thereof equal to the fraction of one share of Common Stock to which such stockholder would otherwise be entitled multiplied by the closing price of the Common Stock as reported on the Nasdaq Capital Market on the trading day immediately preceding the Effective Time, without interest or deduction. The cash payment will be subject to applicable U.S. federal, state and local income taxes. See the section entitled “Certain U.S. Federal Income Tax Consequences” below for a more detailed discussion of the tax consequences of the receipt of cash in lieu of fractional shares.
As of the Record Date, there were approximately 37 stockholders of record of our Common Stock (although there are a significantly larger number of beneficial owners of our Common Stock). Upon stockholder approval of the Reverse Stock Split Proposal, if the Board elects to implement the Reverse Stock Split, the Company does not expect that cashing out fractional stockholders would significantly reduce the number of stockholders of record. Reducing the number of post-split stockholders, however, is not the purpose of this proposal.
Stockholders should be aware that, under the escheat laws of the various jurisdictions where stockholders reside, where the Company is domiciled and where the funds will be deposited, sums due for fractional interests that are not timely claimed after the Effective Time may be required to be paid to the designated agent for each such jurisdiction, unless correspondence has been received by the Company or the exchange agent concerning ownership of such funds within the time permitted in such jurisdiction. Thereafter, stockholders otherwise entitled to receive such funds will have to seek to obtain them directly from the state to which they were paid.
With respect to outstanding awards under the Equity Plans, upon the effectiveness of the Reverse Stock Split, the number of shares subject to outstanding awards and the exercise price per share (as applicable) will be proportionately adjusted in accordance with the terms of the applicable Equity Plan and award agreement. Any fractional shares resulting from such adjustment will be rounded down to the nearest whole share, consistent with the requirements of Sections 409A and 424 of the Code.
Illustration of Certain Hypothetical Effects of the Reverse Stock Split
The following table illustrates certain hypothetical effects of the Reverse Stock Split at certain ratios within the proposed range, without giving effect to any adjustments for fractional shares of Common Stock, based on share information as of the Record Date:
 
 
 
 
 
 
 
 
 
 
Pre-Reverse
Stock Split
 
 
Post-Reverse Stock Split
 
 
 
10:1
 
 
25:1
 
 
35:1
Authorized
 
 
300,000,000
 
 
300,000,000
 
 
300,000,000
 
 
300,000,000
Outstanding
 
 
114,856,548
 
 
11,485,654
 
 
4,594,261
 
 
3,281,615
Reserved for issuance upon issuance of common stock warrants
 
 
19,016,707
 
 
1,901,670
 
 
760,668
 
 
543,334
Reserved for issuance upon exercise of pre-funded warrants
 
 
31,346,152
 
 
3,134,615
 
 
1,253,846
 
 
895,604
Reserved for future issuance pursuant to the outstanding options and restricted stock units
 
 
10,107,211
 
 
1,010,721
 
 
404,288
 
 
288,777
Reserved for future issuance pursuant to the Equity Plans
 
 
1,625,878
 
 
162,587
 
 
65,035
 
 
46,453
Authorized but unissued and unreserved
 
 
123,047,504
 
 
282,304,753
 
 
292,921,902
 
 
294,944,217
 
 
 
 
 
 
 
 
 
 
 
 
 
11

TABLE OF CONTENTS

After the Reverse Stock Split, the Common Stock will continue to be listed on the Nasdaq Capital Market under the symbol “PDSB.” In accordance with Nasdaq rules, a “D” will be appended to the trading symbol for a period of approximately 20 trading days following the Effective Time to indicate that the Reverse Stock Split has occurred. In addition, following the Reverse Stock Split, the CUSIP number for the Common Stock will change.
Certain Risks and Potential Disadvantages Associated with the Reverse Stock Split
If the Reverse Stock Split is implemented, some stockholders may consequently own less than one hundred shares of the Common Stock. A purchase or sale of less than one hundred shares (an “odd lot” transaction) may result in incrementally higher trading costs through certain brokers, particularly “full service” brokers. Therefore, those stockholders who own less than one hundred shares following the Reverse Stock Split may be required to pay modestly higher transaction costs should they then determine to sell their share of Common Stock.
The effect of the Reverse Stock Split upon the market prices for the Common Stock cannot be accurately predicted, and the history of similar stock split combinations for companies in like circumstances is varied. In particular, there is no assurance that the price per share of the Common Stock after the Reverse Stock Split will be between 10 and 35 times, as applicable, the price per share of the Common Stock immediately prior to the Reverse Stock Split. Furthermore, there can be no assurance that the market price of the Common Stock immediately after the proposed Reverse Stock Split will be maintained for any period of time. Even if an increased share price can be maintained, the Reverse Stock Split may not achieve the other desired results that have been outlined above. In particular, we cannot assure you that the proposed Reverse Stock Split will increase our stock price and have the desired effect of allowing us to maintain compliance with applicable Nasdaq rules for listing on the Nasdaq Capital Market. Moreover, because some investors may view the Reverse Stock Split negatively, there can be no assurance that approval of the Reverse Stock Split will not adversely impact the market price of the Common Stock or, alternatively, that the market price following the Reverse Stock Split will either exceed or remain in excess of the current market price.
In addition, although we believe the Reverse Stock Split may enhance the desirability of the Common Stock to certain potential investors, we cannot assure you that, if implemented, the Common Stock will be more attractive to institutional and other long-term investors. In addition, the Reverse Stock Split may decrease, or may not increase, the liquidity of the Common Stock since there would be a reduced number of shares outstanding after the Reverse Stock Split.
The Reverse Stock Split may be viewed negatively by the market and, consequently, could lead to a decrease in our overall market capitalization. If the per share market price of the Common Stock does not increase in proportion to the reverse stock split ratio, then the value of the Company, as measured by our market capitalization, will be reduced. Additionally, any reduction in our market capitalization may be magnified as a result of the smaller number of total shares of the Common Stock outstanding following the Reverse Stock Split.
Effective Time
The Reverse Stock Split will become effective upon the filing of the certificate of amendment to the Charter (the “Certificate of Amendment”) with the Delaware Secretary of State or at such later time as is specified therein. If the Reverse Stock Split Proposal is approved, it is expected that the Certificate of Amendment will be filed promptly following the Special Meeting with a specified effective time, subject to the Board not having determined to abandon the Reverse Stock Split. The Board reserves the right to abandon the Reverse Stock Split at any time on or before December 31, 2027, without further action by the stockholders.
Exchange of Stock Certificates
As of the Effective Time, each certificate representing pre-Reverse Stock Split shares of Common Stock will be deemed for all purposes to evidence ownership of and represent the reduced number of whole shares of Common Stock resulting from the Reverse Stock Split. Computershare Trust Company, N.A., our transfer agent, will act as exchange agent for purposes of implementing the exchange of stock certificates (the “Exchange Agent”). As soon as practicable after the Effective Time, stockholders of record will be sent a transmittal form by the Exchange Agent with instructions for the surrender of certificate(s) representing pre-split shares in exchange for certificate(s) or book-entry statements representing the number of whole post-split shares and cash in lieu of any fractional shares.
STOCKHOLDERS SHOULD NOT DESTROY ANY STOCK CERTIFICATES AND SHOULD NOT SUBMIT THEIR STOCK CERTIFICATES UNTIL THEY RECEIVE A TRANSMITTAL FORM FROM OUR
12

TABLE OF CONTENTS

EXCHANGE AGENT. STOCKHOLDERS ARE ENCOURAGED TO PROMPTLY SURRENDER CERTIFICATES TO THE EXCHANGE AGENT FOLLOWING RECEIPT OF TRANSMITTAL FORMS IN ORDER TO AVOID HAVING SHARES POSSIBLY BECOMING SUBJECT TO ESCHEAT LAWS.
Stockholders whose shares are held in brokerage accounts or in “street name” are not required to take any action to effect the exchange of their shares of Common Stock. Such stockholders who have questions regarding the exchange of their shares should contact their broker.
Accounting Consequences
The par value per share of Common Stock will remain unchanged at $0.00033 per share after the Reverse Stock Split. As a result, on the Effective Time, the stated capital on the Company’s balance sheet attributable to the Common Stock will be reduced in proportion to the Reverse Stock Split ratio, and the additional paid-in capital account will be credited with the amount by which the stated capital is reduced. After the Reverse Stock Split, per share net loss will be increased because there will be fewer shares of Common Stock outstanding. The Company does not anticipate that any other accounting consequences would arise as a result of the Reverse Stock Split.
Potential Anti-Takeover Effect
Although the increased proportion of unissued authorized shares to issued shares could, under certain circumstances, have an anti-takeover effect (for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the Board or contemplating a tender offer or other transaction for the combination of the Company with another company), the Reverse Stock Split Proposal is not being proposed in response to any effort of which the Company is aware to accumulate shares of Common Stock or obtain control of the Company, nor is it part of a plan by management to recommend a series of similar amendments to the Board and stockholders.
No Appraisal Rights
Under the DGCL, the Company’s stockholders are not entitled to dissenter’s or appraisal rights with respect to the Reverse Stock Split, and the Company will not independently provide stockholders with any such rights.
Regulatory Approvals
No regulatory approvals are required in connection with the Reverse Stock Split other than the filing of the Certificate of Amendment with the Delaware Secretary of State and the submission of the Company Event Notification Form and related materials to Nasdaq at least ten calendar days prior to the anticipated market effective date of the Reverse Stock Split, together with public disclosure of the Reverse Stock Split at least two business days prior to such date, each as required by Nasdaq Listing Rules.
Certain U.S. Federal Income Tax Consequences
The following is a summary of certain U.S. federal income tax consequences of the Reverse Stock Split that may be relevant to holders of Common Stock. This summary is based upon the provisions of the Code, Treasury Regulations promulgated thereunder, administrative rulings and judicial decisions, all as of the date hereof, any of which may subsequently be changed, possibly retroactively, so as to result in U.S. federal income tax consequences different from those discussed below.
This summary does not address all aspects of U.S. federal income taxation that may be relevant to holders in light of their particular circumstances or to holders who may be subject to special tax rules, including, without limitation: (i) holders subject to the alternative minimum tax; (ii) banks, insurance companies, or other financial institutions; (iii) tax-exempt organizations; (iv) dealers in securities or commodities; (v) regulated investment companies or real estate investment trusts; (vi) partnerships (or other flow-through entities for U.S. federal income tax purposes and their partners or members); (vii) traders in securities that elect to use a mark-to-market method of accounting for their securities holdings; (viii) U.S. holders (as defined below) whose “functional currency” is not the U.S. dollar; (ix) persons holding Common Stock as a position in a hedging transaction, “straddle,” “conversion transaction” or other risk reduction transaction; (x) persons who acquire shares of Common Stock in connection with employment or other performance of services; or (xi) U.S. expatriates or former residents of the United States.
13

TABLE OF CONTENTS

If a partnership (including any entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds shares of Common Stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partnership.
THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT INTENDED AS TAX ADVICE. HOLDERS OF THE COMMON STOCK SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT ARISING UNDER OTHER U.S. FEDERAL TAX LAWS (INCLUDING ESTATE AND GIFT TAX LAWS), UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE TAX TREATY.
Tax Consequences to U.S. Holders
As used herein, the term “U.S. holder” means a beneficial owner of shares of Common Stock that is, for U.S. federal income tax purposes: (i) an individual who is a citizen or resident of the United States; (ii) a corporation (or other entity taxable as a corporation) created or organized in or under the laws of the United States, any state thereof or the District of Columbia; (iii) an estate the income of which is subject to U.S. federal income taxation regardless of its source; or (iv) a trust if (a) its administration is subject to the primary supervision of a court within the United States and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (b) it has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.
The Reverse Stock Split is intended to be treated as a “recapitalization” for U.S. federal income tax purposes. Assuming the Reverse Stock Split qualifies as a recapitalization, a U.S. holder generally will not recognize gain or loss upon the exchange of pre-split shares for post-split shares, except with respect to cash received in lieu of a fractional share of Common Stock (as discussed below).
A U.S. holder’s aggregate tax basis in the post-split shares received in the Reverse Stock Split will equal the U.S. holder’s aggregate tax basis in the pre-split shares exchanged therefor (reduced by the amount of the basis allocated to any fractional share for which cash is received). The holding period of the post-split shares received in the Reverse Stock Split will include the holding period of the pre-split shares exchanged therefor.
The tax treatment of cash received in lieu of a fractional share is not entirely clear. A U.S. holder who receives cash in lieu of a fractional share of post-split Common Stock may recognize capital gain or loss in an amount equal to the difference between the amount of cash received and the U.S. holder’s tax basis in the fractional share. Such capital gain or loss will be long-term capital gain or loss if the U.S. holder’s holding period for the pre-split shares exceeds one year as of the Effective Time. Alternatively, the cash received in lieu of a fractional share may be treated as a distribution under Section 301 of the Code.
A U.S. holder of Common Stock may be subject to information reporting and backup withholding (currently at a rate of 24%) on cash paid in lieu of a fractional share in connection with the Reverse Stock Split. A U.S. holder of Common Stock will not be subject to backup withholding, however, if the U.S. holder furnishes a correct taxpayer identification number and certifies that the U.S. holder is not subject to backup withholding on the substitute Form W-9 included in the transmittal form, or otherwise proves an exemption from backup withholding. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against the U.S. holder’s federal income tax liability, if any, provided the required information is timely furnished to the IRS.
Tax Consequences to Non-U.S. Holders
As used herein, the term “Non-U.S. holder” means a beneficial owner of shares of Common Stock that is not a U.S. holder and is not a partnership (or other entity or arrangement treated as a partnership) for U.S. federal income tax purposes.
A Non-U.S. holder generally will not recognize gain or loss upon the exchange of pre-split shares for post-split shares in the Reverse Stock Split.
The tax treatment of cash received in lieu of a fractional share by a Non-U.S. holder is not entirely clear. Such cash payment may be treated as gain from the disposition of shares of Common Stock or as a distribution under Section 301 of the Code.
14

TABLE OF CONTENTS

If the cash received in lieu of a fractional share is treated as gain from the disposition of shares of Common Stock, a Non-U.S. holder generally will not be subject to U.S. federal income tax on such gain unless: (i) the gain is effectively connected with the conduct of a trade or business by the Non-U.S. holder within the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment maintained by such Non-U.S. holder in the United States), in which case the Non-U.S. holder will generally be subject to tax on the net gain derived from the disposition at the regular rates and in the manner applicable to U.S. persons (unless an applicable income tax treaty provides otherwise) and, if the Non-U.S. holder is a corporation, may also be subject to an additional branch profits tax at a 30% rate (or such lower rate as may be specified by an applicable income tax treaty); (ii) the Non-U.S. holder is a nonresident alien individual who is present in the United States for 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the Non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty) on the gain derived from the disposition, which may be offset by U.S.-source capital losses of the Non-U.S. holder, if any; or (iii) the Company is or has been a “United States real property holding corporation” (“USRPHC”) for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the Non-U.S. holder held the Common Stock. The Company does not believe it is or has been a USRPHC.
If the cash received in lieu of a fractional share is treated as a distribution under Section 301 of the Code, it could be treated as a dividend to the extent of the Company’s current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Such dividends paid to a Non-U.S. holder generally would be subject to withholding of U.S. federal income tax at a 30% rate (or such lower rate as may be specified by an applicable income tax treaty).
A Non-U.S. holder may be subject to backup withholding on cash received in lieu of a fractional share unless the Non-U.S. holder complies with certain certification procedures (usually by providing an IRS Form W-8BEN or W-8BEN-E) or otherwise establishes an exemption.
Interests of Certain Persons in the Proposal
The Company’s officers and directors have an interest in the Reverse Stock Split Proposal only to the extent of their ownership of shares of Common Stock and awards granted under the Equity Plans. The officers and directors of the Company do not have any interest in the Reverse Stock Split Proposal that is different from or greater than the interest of any other stockholder of the Company.
Vote Required
Approval of the Reverse Stock Split Proposal requires the affirmative vote of a majority of the votes cast on the proposal, in accordance with Section 242(d)(2) of the DGCL. Abstentions are not considered votes cast and will have no effect on the outcome of this proposal. Broker non-votes, if any, are also not considered votes cast and will have no effect on the outcome of this proposal.
THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE APPROVAL OF THE AMENDMENT TO THE EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO EFFECT, IN THE SOLE DISCRETION OF THE BOARD, AT ANY TIME ON OR BEFORE DECEMBER 31, 2027, A REVERSE STOCK SPLIT OF THE COMMON STOCK AT A RATIO TO BE DETERMINED BY THE BOARD, WITHIN A RANGE OF 1-FOR-10 TO 1-FOR-35 (OR ANY WHOLE NUMBER IN BETWEEN), WITHOUT REDUCING THE AUTHORIZED NUMBER OF SHARES OF THE COMMON STOCK, AND WITHOUT FURTHER APPROVAL OR AUTHORIZATION OF OUR STOCKHOLDERS.
15

TABLE OF CONTENTS

PROPOSAL 2
 
ADJOURNMENT PROPOSAL
Background of and Rationale for the Adjournment Proposal
The Board believes that, if the number of votes cast in favor of the Reverse Stock Split Proposal is insufficient to approve such proposal, it is in the best interests of the stockholders to enable the Board to continue to seek to obtain a sufficient number of additional affirmative votes to approve the Reverse Stock Split Proposal.
In the Adjournment Proposal, we are asking stockholders to authorize the holder of any proxy solicited by the Board to vote in favor of adjourning the Special Meeting or any adjournment thereof. If our stockholders approve this proposal, we could adjourn the Special Meeting, and any adjourned session of the Special Meeting, to use the additional time to solicit additional proxies in favor of the Reverse Stock Split Proposal.
Additionally, approval of the Adjournment Proposal could mean that, in the event we receive proxies indicating that a majority of the votes cast on the Reverse Stock Split Proposal would be cast against such proposal, we could adjourn the Special Meeting without a vote on the Reverse Stock Split Proposal and use the additional time to solicit the holders of those shares to change their vote in favor of the proposal.
If it is necessary or appropriate (as determined in good faith by the Board) to adjourn the Special Meeting, no notice of the adjourned meeting is required to be given to our stockholders under Delaware law, other than an announcement at the Special Meeting of the time and place to which the Special Meeting is adjourned, so long as the meeting is adjourned for 30 days or less and no new record date is fixed for the adjourned meeting. At the adjourned meeting, we may transact any business which might have been transacted at the original meeting.
Interests of Certain Persons in the Proposal
We do not believe that our officers or directors have interests in the Adjournment Proposal that are different from or greater than those of any other of our stockholders.
Vote Required
The approval of the Adjournment Proposal requires the affirmative vote of the majority of the shares of our Common Stock present in person or by remote communication, if applicable, or represented by proxy at the Special Meeting and entitled to vote thereon. Abstentions will have the effect of a vote against this proposal, and broker non-votes will have no effect.
THE BOARD RECOMMENDS A VOTE “FOR” THE ADJOURNMENT OF THE SPECIAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE INSUFFICIENT VOTES AT THE TIME OF THE SPECIAL MEETING TO APPROVE THE REVERSE STOCK SPLIT PROPOSAL.
16

TABLE OF CONTENTS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. In accordance with SEC rules, shares of our common stock which may be acquired upon exercise of stock options or warrants which are currently exercisable or which become exercisable within 60 days of the date of the applicable table below are deemed beneficially owned by the holders of such options and warrants and are deemed outstanding for the purpose of computing the percentage of ownership of such person, but are not treated as outstanding for the purpose of computing the percentage of ownership of any other person. Subject to community property laws, where applicable, the persons or entities named in the tables below have sole voting and investment power with respect to all shares of our common stock indicated as beneficially owned by them.
The following table sets forth information with respect to the beneficial ownership of our common stock as of the Record Date, by (i) each stockholder known by us to be the beneficial owner of more than 5% of our common stock (our only classes of voting securities), (ii) each of our directors, (iii) each of our named executive officers and (iv) all of our directors and executive officers as a group. To the best of our knowledge, except as otherwise indicated, each of the persons named in the table has sole voting and investment power with respect to the shares of our common stock beneficially owned by such person, except to the extent such power may be shared with a spouse. To our knowledge, none of the shares listed below are held under a voting trust or similar agreement, except as noted.
Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o PDS Biotechnology Corporation, 303A College Road East, Princeton, NJ 08540.
 
 
 
 
 
 
 
Beneficial Ownership
Name of Beneficial Owner
 
 
Shares
 
 
%(1)
Greater than 5% Stockholders:
 
 
 
 
 
 
Nant Capital, LLC(2)
 
 
22,856,453
 
 
19.9%
PDS Biotech Named Executive Officers and Directors:
 
 
 
 
 
 
Frank Bedu-Addo, Ph.D.(3)
 
 
5,649,806
 
 
4.7%
Patrick Soon-Shiong, M.D.(2)
 
 
22,856,453
 
 
19.9%
James Banaag
 
 
—
 
 
—
John Dawson CBE
 
 
—
 
 
—
Ilian Iliev, Ph.D.(4)
 
 
65,074
 
 
*
Deborah Ramsdell
 
 
—
 
 
—
Bruce Wendel
 
 
—
 
 
—
Kirk Shephard(5)
 
 
286,815
 
 
*
Stephan Toutain(6)
 
 
—
 
 
—
All current executive officers and directors as a group (10 persons)(7)
 
 
29,923,829
 
 
24.7%
 
 
 
 
 
 
 
*
Less than 1%
(1)
Percentage ownership is based on 114,856,548 shares of common stock outstanding as of the Record Date, together with securities exercisable or convertible into shares of common stock within 60 days of such date for each stockholder. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities.
(2)
Consists of 22,856,453 shares of common stock held by Nant Capital, LLC, over which Nant Capital, LLC has sole voting and dispositive power. Dr. Patrick Soon-Shiong, a member of our Board, is the sole member of Nant Capital, LLC and may be deemed to beneficially own the shares held by Nant Capital, LLC . Dr. Soon-Shiong was appointed to the Board effective September 14, 2026 as a designee of Nant Capital, LLC pursuant to a securities purchase agreement, dated September 7, 2026, in connection with the Company’s private placement transaction. Excludes 30,240,892 shares issuable upon exercise of pre-funded warrants held by Nant Capital, LLC, which are subject to an exercise limitation prohibiting exercise to the extent the holder would beneficially own more than 19.9% of the outstanding common stock (which limitation may be adjusted upon 61 days’ notice, but not above 19.99%). The address of Nant Capital, LLC is 450 Duley Road, El Segundo, CA 90245. Information in this footnote regarding the holdings of Nant Capital, LLC is based on Amendment No. 1 to Schedule 13D jointly filed by Nant Capital, LLC and Dr. Soon-Shiong with the SEC on November 12, 2026.
(3)
Includes 690,866 shares of common stock and 4,958,940 shares subject to outstanding options exercisable within 60 days of the Record Date.
(4)
Includes 65,074 shares subject to outstanding options exercisable within 60 days of the Record Date.
(5)
Includes 286,815 shares subject to outstanding options exercisable within 60 days of the Record Date.
(6)
Mr. Toutain ceased serving as the Company’s Chief Operating Officer effective August 21, 2026, and is no longer employed by the Company.
(7)
Includes 6,252,921 shares subject to outstanding options exercisable within 60 days of the Record Date.
17

TABLE OF CONTENTS

HOUSEHOLDING OF PROXY MATERIALS
The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for mailing of Proxy Materials or other Special Meeting materials with respect to two or more stockholders sharing the same address by delivering a single mailing of Proxy Materials or other Special Meeting materials addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially means extra convenience for stockholders and cost savings for companies.
In connection with the Special Meeting, a number of brokers with account holders who are PDS Biotech stockholders will be “householding” our Proxy Materials. A single mailing of Proxy Materials or other Special Meeting materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be “householding” communications to your address, “householding” will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in “householding” and would prefer to receive a separate mailing of Proxy Materials, please notify us or your broker. Direct your written request to Investor Relations, PDS Biotechnology Corporation at 303A College Road East, Princeton, NJ 08540 or by phone at (800) 208-3343. Stockholders who currently receive multiple copies of Proxy Materials at their addresses and would like to request “householding” of their communications should contact their brokers.
18

TABLE OF CONTENTS

WHERE YOU CAN FIND ADDITIONAL INFORMATION
The Company is subject to the informational requirements of the Exchange Act, and in accordance therewith, files annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that file electronically with the SEC.
Copies of the Company’s annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are also available free of charge through the Company’s website at www.pdsbiotech.com as soon as reasonably practicable after electronically filing such material with, or furnishing such material to, the SEC.
You may also contact Spencer Brown at (800) 208-3343 if you have any questions or need additional copies of this proxy statement.
19

TABLE OF CONTENTS

OTHER MATTERS
The Board knows of no other matters that will be presented for consideration at the Special Meeting. If any other matters are properly brought before the Special Meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment.
By Order of the Board of Directors
Frank Bedu-Addo, Ph.D.
Chief Executive Officer
November [ ], 2026
This Proxy Statement is available free of charge at www.proxyvote.com.
20

TABLE OF CONTENTS

APPENDIX A
 
CERTIFICATE OF AMENDMENT
TO THE
EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
PDS BIOTECHNOLOGY CORPORATION
PDS Biotechnology Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”),
DOES HEREBY CERTIFY THAT:
FIRST: The name of the Corporation is PDS Biotechnology Corporation.
SECOND: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending its Eighth Amended and Restated Certificate of Incorporation, as amended (the “Charter”), as follows:
RESOLVED, that ARTICLE IV - CAPITALIZATION of the Charter is hereby amended to add the following new subsection (e):
“(e) Reverse Split. At [•] [a.m./p.m.] Eastern Time on [•] (the “Effective Time”), each [•]* shares of Common Stock, par value $0.00033 per share, issued and outstanding or held by the Corporation as treasury stock immediately prior to the Effective Time shall be combined into one (1) validly issued, fully paid and non-assessable share of Common Stock, without any further action by the Corporation or the holder thereof (the “Reverse Stock Split”); provided, however, that no fractional shares shall be issued to any holder and instead, stockholders who otherwise would be entitled to receive fractional shares of Common Stock shall be entitled to receive cash (without interest or deduction) equal to the fraction of one share to which such stockholder would otherwise be entitled multiplied by the closing price of the Common Stock as reported on the Nasdaq Capital Market on the trading day immediately preceding the effective date of the Reverse Stock Split. Each certificate that, immediately prior to the Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Effective Time (“Old Certificates”), shall, from and after the Effective Time, represent that whole number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificates shall have been combined, subject to the treatment of fractional shares as described above.”
THIRD: That this Certificate of Amendment was submitted to the stockholders of the Corporation for their approval and was duly adopted at a Special Meeting of Stockholders held on December [•], 2026, in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.
FOURTH: All other provisions of the Charter shall remain in full force and effect.
FIFTH: That this Certificate of Amendment to the Charter shall be effective at the Effective Time.
IN WITNESS WHEREOF, the undersigned has executed this Certificate of Amendment as of the    day of [•], 2026.
 
 
 
 
 
 
 
PDS BIOTECHNOLOGY CORPORATION
 
 
 
 
 
 
 
 
 
 
By:
 
 
 
 
 
 
Name:
 
 
Frank Bedu-Addo, Ph.D.
 
 
 
Title:
 
 
President and Chief Executive Officer
 
 
 
 
 
 
 
*
This amendment approves the combination of any whole number of shares of Common Stock between and including 10 and 35 into one (1) share of Common Stock. By approving this amendment, the stockholders would approve each of the alternative amendments proposed.
A-1

TABLE OF CONTENTS


 

TABLE OF CONTENTS


 

Keep reading